XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Cash flows from operating activities:      
Net cash provided by (used in) operating activities   $ 1,400 $ 225,424
Cash flows from investing activities:      
Proceeds from sale of property and equipment   24 1
Purchases of property and equipment   (1,862) (3,793)
Purchases of equity securities   (24,820) (55,273)
Purchases of available-for-sale debt securities   (72,698) (134,899)
Proceeds from sales of equity securities $ 34,444 37,233 17,692
Proceeds from sales of available-for-sale debt securities   3,695 19,534
Maturities of available-for-sale debt securities   43,032 33,683
Net cash provided by (used in) investing activities   (15,396) (123,055)
Cash flows from financing activities:      
Debt issuance costs paid   0 (131)
Preferred stock dividend   (5) (5)
Common stock dividend   (9,885) (9,974)
Purchase of treasury stock   (6,088) (7,381)
Payments related to tax withholding for share-based compensation   (314) (209)
Repayment of debt   (736) (735)
Net cash provided by (used in) financing activities   (17,028) (18,435)
Cash and cash equivalents and restricted cash and cash equivalents:      
Net increase (decrease) during the period   (31,024) 83,934
Balance, beginning of period   391,341 253,143
Balance, end of period 360,317 360,317 337,077
Cash and cash equivalents, and restricted cash and cash equivalents within the Consolidated Balance Sheets      
Cash and cash equivalents 291,681 291,681  
Restricted cash and cash equivalents 68,636 [1] 68,636 [1]  
Total cash and cash equivalents and restricted cash and cash equivalents $ 360,317 $ 360,317 $ 337,077
[1] See “—Note 5 (Insurance Operations)” for a discussion of the nature of the restrictions for restricted cash and cash equivalents and "—Note 14(Variable Interest Entities)” for a discussion of restricted cash held in a trust account.